

Supplementary Table 4. Odds ratios (OR) with 95% confidence intervals (CIs) for NAFLD according to the presence of obesity (with additional adjustment)

Model		Without obesity			With obesity		
		OR	95% CI	P-value	OR	95% CI	P-value
For sarcopenia							
Men	Sarcopenia	1.21	0.90–1.61	0.207	1.09	0.84–1.34	0.512
	VFO	3.37	2.91–3.92	<0.001	1.78	1.50–2.12	<0.001
	Diabetes	2.12	1.71–2.63	<0.001	2.52	1.95–3.26	<0.001
	High CRP	1.17	0.94–1.45	0.169	1.63	1.28–2.08	<0.001
Women	Sarcopenia	1.49	1.13–1.96	0.005	1.13	0.88–1.47	0.338
	VFO	4.75	4.01–5.64	<0.001	2.92	2.25–3.78	<0.001
	Diabetes	3.63	2.76–4.77	<0.001	3.49	2.25–3.78	<0.001
	High CRP	1.06	0.79–1.42	0.701	2.15	1.57–2.95	<0.001
	Menopause	1.71	1.27–2.32	0.020	1.60	1.03–2.47	0.035
For myosteatorsis							
Men	Myosteatorsis	1.21	0.99–1.49	0.056	1.06	0.89–1.27	0.512
	VFO	3.36	2.89–3.80	<0.001	1.78	1.49–2.11	<0.001
	Diabetes	2.14	1.73–3.90	<0.001	2.52	1.95–3.26	<0.001
	High CRP	1.16	0.93–1.44	0.194	1.78	1.49–2.11	<0.001
Women	Myosteatorsis	1.26	1.06–1.49	0.009	0.92	0.70–1.20	0.538
	VFO	4.66	3.93–5.54	<0.001	2.88	2.22–3.73	<0.001
	Diabetes	3.62	2.76–4.76	<0.001	3.45	2.34–5.09	<0.001
	High CRP	1.26	0.78–1.40	0.752	2.20	1.61–3.02	<0.001
	Menopause	1.69	1.26–2.29	0.011	1.62	1.05–2.90	0.037
For sarcopenia with myosteatorsis							
Men	Sarcopenia with myosteatorsis	1.27	0.93–1.95	0.116	1.17	0.86–1.59	0.322
	VFO	3.36	2.89–3.90	<0.001	1.78	1.50–2.12	<0.001
	Diabetes	2.13	1.72–2.64	<0.001	2.52	1.95–3.26	<0.001
	High CRP	1.56	0.93–1.44	0.970	1.62	1.27–2.07	<0.001
Women	Sarcopenia with myosteatorsis	1.48	1.07–2.06	0.019	1.04	0.73–1.48	0.826
	VFO	4.69	3.94–5.56	<0.001	2.91	2.25–3.78	<0.001
	Diabetes	3.65	2.77–4.80	<0.001	3.48	2.38–5.14	<0.001
	High CRP	1.05	0.78–1.40	0.757	2.16	1.58–2.97	<0.001
	Menopause	1.64	1.28–2.10	<0.001	1.65	1.13–2.39	0.009

NAFLD, non-alcoholic fatty liver disease; VFO, visceral fat obesity; hsCRP, high-sensitivity C-reactive protein.

Adjusted for age, regular aerobic exercise, regular resistance exercise, VFO, diabetes, hypertension, high CRP, TG, HDL-cholesterol, menopausal status (only adjusted in women), and sarcopenia and/or myosteatorsis.